Mineola, New York 11501

  • Proteinuric Renal Disease


Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression and cardiovascular outcomes. Deficiency of 1-25 Vitamin D develops early in CKD, and is undertreated. Vitamin D may have important effects on factors that drive proteinuria and renal disease progression in patients with proteinuric renal diseases. Therefore, Paricalcitol treatment may reduce proteinuria and slow renal deterioration.

Study summary:

Objectives: 1. To determine the effect of oral paricalcitol on protein excretion in patients with proteinuric renal diseases 2. To determine the effect of oral paricalcitol on renal disease progression in patients with proteinuric renal diseases Hypothesis: Oral paricalcitol will reduce protein excretion in proteinuric kidney disease Study Design: Prospective, randomized, placebo controlled, double blind, trial of paricalcitol compared to placebo. Sample Size: 60 patients, 30 in each group Summary of Patient Eligibility Criteria: Subjects with proteinuric renal disease (>400 mg/24 hours) Randomization and Dosage: Patients will be randomized to treatment with oral paricalcitol (initial dose 1 mcg orally per day) compared to placebo Duration : 6 Months


Inclusion Criteria: 1. Stable chronic kidney disease 2. Urine protein : Creatinine ratio > 0.4 3. Chronic kidney disease stage 2-4 with eGFR 15-90 ml/min 4. PTH (intact) >20 pg/ml and <250 pg/ml 5. Age 18-85 6. If on ACEI/ARB, then dose optimized (BP, K) Exclusion Criteria: 1. Failure to provide informed consent 2. Glomerunephritis requiring active treatment with immunosuppresive therapy 3. Serum phosphorus > 5.2 4. Serum calcium (adjusted for albumin)> 10.0 5. Active malignancy 6. Likelihood of requiring renal replacement therapy within 1 year 7. Uncontrolled hypertension



Primary Contact:

Study Chair
Alex Schoen
Winthrop University Hospital

Steven Fishbane, MD
Phone: 516-663-2169
Email: sfishbane@metrorenal.com

Backup Contact:


Location Contact:

Mineola, New York 11501
United States

Steven Fishbane, MD
Phone: 516-663-2169

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: December 08, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.